The Global Initiative for Asthma (GINA) is a network of individuals, organizations, and public health officials that was established to disseminate information about the care of patients with asthma and to improve asthma care. The GINA (“Global Strategy for Asthma Management and Prevention”) report has been updated annually since 2002. Due to new knowledge and therapeutic development in the field, the Swiss Respiratory Society felt the need to provide a new document that is based on both the available literature and the recommendations of the 2016 GINA report. Key new features of the 2016 GINA report include a “new” definition of asthma, underscoring its heterogeneous nature, and the core elements of variable symptoms and variable expiratory airflow limitation; the importance of confirming the diagnosis of asthma in order to minimize both under- and overtreatment; practical tools for the assessment of symptom control and risk factors for adverse outcomes; a comprehensive approach to asthma management that acknowledges the foundational role of inhaled corticosteroid therapy, but also provides a framework for individualizing patient care; an emphasis on maximizing the benefit of available medications by addressing common problems such as incorrect inhaler technique and poor adherence; a continuum of care for worsening asthma, starting with early self-management and progressing to primary care or acute care management; and diagnosis of the asthma/chronic obstructive pulmonary disease overlap syndrome. This document is meant to advice the key stakeholders on the diagnosis and management of asthma and highlights the need to individualize the care of each and every asthmatic patient.

Keywords:
Asthma, Diagnosis, Therapy, Treatment, Swiss guidelines
1.
Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ: Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161: 309–329.
2.
Joos GF, O’Connor B, Anderson SD, Chung F, Cockcroft DW, Dahlén B, DiMaria G, Foresi A, Hargreave FE, Holgate ST, Inman M, Lötvall J, Magnussen H, Polosa R, Postma DS, Riedler J; ERS Task Force: Indirect airway challenges. Eur Respir J 2003; 21: 1050–1068. Erratum in: Eur Respir J 2003; 22: 718.
3.
Global strategy for asthma management and prevention. www.ginasthma.org (updated 2016).
4.
Bel EH: Clinical phenotypes of asthma. Curr Opin Pulm Med 2004; 10: 44–50.
5.
Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D’Agostino R Jr, Castro M, Curran-Everett D, Fitzpatrick AM, Gaston B, Jarjour NN, Sorkness R, Calhoun WJ, Chung KF, Comhair SA, Dweik RA, Israel E, Peters SP, Busse WW, Erzurum SC, Bleecker ER; National Heart, Lung, and Blood Institute’s Severe Asthma Research Program: Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315–323.
6.
Wenzel SE: Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716–725.
7.
Siroux V, González JR, Bouzigon E, Curjuric I, Boudier A, Imboden M, Anto JM, Gut I, Jarvis D, Lathrop M, Omenaas ER, Pin I, Wjst M, Demenais F, Probst-Hensch N, Kogevinas M, Kauffmann F: Genetic heterogeneity of asthma phenotypes identified by a clustering approach. Eur Respir J 2014; 43: 439–452.
8.
tenBrinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel H: “Refractory” eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004; 170: 601–605.
9.
Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program: The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469–478.
10.
Van Wonderen KE, Van Der Mark LB, Mohrs J, Bindels PJ, Van Aalderen WM, Ter Riet G: Different definitions in childhood asthma: how dependable is the dependent variable? Eur Respir J 2010; 36: 48–56.
11.
Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S; International Study of Asthma and Allergies in Childhood Phase Three Study Group: Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2009; 64: 476–483.
12.
Wüthrich B, Schmid-Grendelmeier P, Schindler C, Imboden M, Bircher A, Zemp E, Probst-Hensch N: Prevalence of atopy and respiratory allergic diseases in the elderly SAPALDIA population. Int Arch Allergy Immunol 2013; 162: 143–148.
13.
Mehta AJ, Schindler C, Perez L, Probst-Hensch N, Schwartz J, Brändl O, Karrer W, Tschopp JM, Rochat T, Künzli N; SAPALDIA Team: Acute respiratory health effects of urban air pollutants in adults with different patterns of underlying respiratory disease. Swiss Med Wkly 2012; 142:w13681.
14.
Cai Y, Schikowski T, Adam M, Buschka A, Carsin AE, Jacquemin B, Marcon A, Sanchez M, Vierkötter A, Al-Kanaani Z, Beelen R, Birk M, Brunekreef B, Cirach M, Clavel-Chapelon F, Declercq C, de Hoogh K, de Nazelle A, Ducret-Stich RE, Valeria Ferretti V, Forsberg B, Gerbase MW, Hardy R, Heinrich J, Hoek G, Jarvis D, Keidel D, Kuh D, Nieuwenhuijsen MJ, Ragettli MS, Ranzi A, Rochat T, Schindler C, Sugiri D, Temam S, Tsai MY, Varraso R, Kauffmann F, Krämer U, Sunyer J, Künzli N, Probst-Hensch N, Hansell A: Cross-sectional associations between air pollution and chronic bronchitis: an ESCAPE meta-analysis across five cohorts. Thorax 2014; 69: 1005–1014.
15.
Brutsche MH, Downs SH, Schindler C, Gerbase MW, Schwartz J, Frey M, Russi EW, Ackermann-Liebrich U, Leuenberger P; SAPALDIA Team: Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax 2006; 61: 671–677.
16.
Chinn S, Downs SH, Anto JM, Gerbase MW, Leynaert B, de Marco R, Janson C, Jarvis D, Künzli N, Sunyer J, Svanes C, Zemp E, Ackermann-Liebrich U, Burney P; ECRHS; SAPALDIA: Incidence of asthma and net change in symptoms in relation to changes in obesity. Eur Respir J 2006; 28: 763–771.
17.
Sistek D, Tschopp JM, Schindler C, Brutsche M, Ackermann-Liebrich U, Perruchoud AP, Leuenberger P: Clinical diagnosis of current asthma: predictive value of respiratory symptoms in the SAPALDIA study. Swiss Study on Air Pollution and Lung Diseases in Adults. Eur Respir J 2001; 17: 214–219.
18.
Osthoff M, Michel F, Strupler M, Miedinger D, Taegtmeyer AB, Leuppi JD, Perret C: Bronchial hyperresponsiveness testing in athletes of the Swiss Paralympic team. BMC Sports Sci Med Rehabil 2013; 5: 7.
19.
Pearce N, Aït-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, Robertson C; ISAAC Phase Three Study Group: Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007; 62: 758–766.
20.
Bridevaux PO, Probst-Hensch NM, Schindler C, Curjuric I, Felber Dietrich D, Braendli O, Brutsche M, Burdet L, Frey M, Gerbase MW, Ackermann-Liebrich U, Pons M, Tschopp JM, Rochat T, Russi EW: Prevalence of airflow obstruction in smokers and never-smokers in Switzerland. Eur Respir J 2010; 36: 1259–1269.
21.
Aaron SD, Vandemheen KL, FitzGerald JM, Ainslie M, Gupta S, Lemière C, Field SK, McIvor RA, Hernandez P, Mayers I, Mulpuru S, Alvarez GG, Pakhale S, Mallick R, Boulet LP; Canadian Respiratory Research Network: Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA 2017; 317: 269–279.
22.
Looijmans-van den Akker I, van Luijn K, Verheij T: Overdiagnosis of asthma in children in primary care: a retrospective analysis. Br J Gen Pract 2016; 66:e152–e157.
23.
Barnes PJ: Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008; 8: 183–192.
24.
Brusselle GG, Maes T, Bracke KR: Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med 2013; 19: 977–979.
25.
Barnes PJ: Pathophysiology of allergic inflammation. Immunol Rev 2011; 242: 31–50.
26.
Barnes PJ: The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008; 118: 3546–3556.
27.
Al-Muhsen S, Johnson JR, Hamid Q: Remodeling in asthma. J Allergy Clin Immunol 2011; 128: 451–462.
28.
Roth M, Johnson PR, Borger P, Bihl MP, Rüdiger JJ, King GG, Ge Q, Hostettler K, Burgess JK, Black JL, Tamm M: Dysfunctional interaction of C/EBPalpha and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells. N Engl J Med 2004; 351: 560–574.
29.
Borger P, Tamm M, Black JL, Roth M: Asthma: is it due to an abnormal airway smooth muscle cell? Am J Respir Crit Care Med 2006; 174: 367–372.
30.
Barnes PJ: Pathophysiology of asthma. Eur Respir Mon 2003; 23: 84–113.
31.
Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A: Differences between asthma exacerbations and poor asthma control. Lancet 1999; 353: 364–369.
32.
Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J; ERS Global Lung Function Initiative: Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J 2012; 40: 1324–1343.
33.
Coates AL, Wanger J, Cockcroft DW, Culver BH; and the Bronchoprovocation Testing Task Force: Kai-Håkon Carlsen, Diamant Z, Gauvreau G, Hall GL, Hallstrand TS, Horvath I, de Jongh FHC, Joos G, Kaminsky DA, Laube BL, Leuppi JD, Sterk PJ: ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J 2017; 49:pii 1601526.
34.
Parsons JP, Hallstrand TS, Mastronarde JG, Kaminsky DA, Rundell KW, Hull JH, Storms WW, Weiler JM, Cheek FM, Wilson KC, Anderson SD; American Thoracic Society Subcommittee on Exercise-induced Bronchoconstriction: An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med 2013; 187: 1016–1027.
35.
Gibson PG, Chang AB, Glasgow NJ, Holmes PW, Katelaris P, Kemp AS, Landau LI, Mazzone S, Newcombe P, Van Asperen P, Vertigan AE; CICADA: CICADA: cough in children and adults: diagnosis and assessment. Australian cough guidelines summary statement. Med J Aust 2010; 192: 265–271.
36.
Miedinger D, Lavoie KL, L’Archeveque J, Ghezzo H, Malo JL: Identification of clinically significant psychological distress and psychiatric morbidity by examining quality of life in subjects with occupational asthma. Health Qual Life Outcomes 2011; 9: 76.
37.
Miedinger D, Lavoie KL, L’Archevêque J, Ghezzo H, Zunzunuegui MV, Malo JL: Quality-of-life, psychological, and cost outcomes 2 years after diagnosis of occupational asthma. J Occup Environ Med 2011; 53: 231–238.
38.
Adams RJ, Wilson DH, Appleton S, Taylor A, Dal Grande E, Chittleborough CR, Ruffin RE: Underdiagnosed asthma in South Australia. Thorax 2003; 58: 846–850.
39.
Hanania NA, Celli BR, Donohue JF, Martin UJ: Bronchodilator reversibility in COPD. Chest 2011; 140: 1055–1063.
40.
Sciurba FC: Physiologic similarities and differences between COPD and asthma. Chest 2004; 126: 117S–124S.
41.
Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ, Crapo JD, Hersh CP; COPDGene Investigators: The clinical features of the overlap between COPD and asthma. Respir Res 2011; 12: 127.
42.
Boulet LP: Asthma and obesity. Clin Exp Allergy 2013; 43: 8–21.
43.
van Huisstede A, Castro Cabezas M, van de Geijn GJ, Mannaerts GH, Njo TL, Taube C, Hiemstra PS, Braunstahl GJ: Underdiagnosis and overdiagnosis of asthma in the morbidly obese. Respir Med 2013; 107: 1356–1364.
44.
Aaron SD, Vandemheen KL, Boulet LP, McIvor RA, Fitzgerald JM, Hernandez P, Lemiere C, Sharma S, Field SK, Alvarez GG, Dales RE, Doucette S, Fergusson D; Canadian Respiratory Clinical Research Consortium: Overdiagnosis of asthma in obese and nonobese adults. Can Med Assoc J 2008; 179: 1121–1131.
45.
Lucas AE, Smeenk FW, Smeele IJ, van Schayck CP: Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory study. Fam Pract 2008; 25: 86–91.
46.
Marklund B, Tunsater A, Bengtsson C: How often is the diagnosis bronchial asthma correct? Fam Pract 1999; 16: 112–116.
47.
Montnémery P, Hansson L, Lanke J, Lindholm LH, Nyberg P, Löfdahl CG, Adelroth E: Accuracy of a first diagnosis of asthma in primary health care. Fam Pract 2002; 19: 365–368.
48.
Taegtmeyer AB, Steurer-Stey C, Price DB, Wildhaber JH, Spertini F, Leuppi JD: Predictors of asthma control in everyday clinical practice in Switzerland. Curr Med Res Opin 2009; 25: 2549–2555.
49.
Juniper EF: Assessing asthma control. Curr Allergy Asthma Rep 2007; 7: 390–394.
50.
Miedinger D, Neukomm E, Chhajed PN, Schnyder A, Naef M, Ackermann M, Leuppi JD: The use of the Asthma Control Test in general practice and its correlation with asthma control according to the GINA guidelines. Curr Med Res Opin 2011; 27: 2301–2308.
51.
Leuppi JD, Steurer-Stey C, Peter M, Chhajed PN, Wildhaber JH, Spertini F: Asthma control in Switzerland: a general practitioner based survey. Curr Med Res Opin 2006; 22: 2159–2166.
52.
Meltzer EO, Busse WW, Wenzel SE, Belozeroff V, Weng HH, Feng J, Chon Y, Chiou CF, Globe D, Lin SL: Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation. J Allergy Clin Immunol 2011; 127: 167–172.
53.
Custovic A, Johnston SL, Pavord I, Gaga M, Fabbri L, Bel EH, Le Souëf P, Lötvall J, Demoly P, Akdis CA, Ryan D, Mäkelä MJ, Martinez F, Holloway JW, Saglani S, O’Byrne P, Papi A, Sergejeva S, Magnan A, Del Giacco S, Kalayci O, Hamelmann E, Papadopoulos NG: EAACI position statement on asthma exacerbations and severe asthma. Allergy 2013; 68: 1520–1531.
54.
Kitch BT, Paltiel AD, Kuntz KM, Dockery DW, Schouten JP, Weiss ST, Fuhlbrigge AL: A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest 2004; 126: 1875–1882.
55.
Ulrik CS: Outcome of asthma: longitudinal changes in lung function. Eur Respir J 1999; 13: 904–918.
56.
Kerstjens HA, Brand PL, de Jong PM, Koëter GH, Postma DS: Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group. Thorax 1994; 49: 1109–1115.
57.
Brand PL, Duiverman EJ, Waalkens HJ, van Essen-Zandvliet EE, Kerrebijn KF: Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group. Thorax 1999; 54: 103–107.
58.
Rosi E, Stendardi L, Binazzi B, Scano G: Perception of airway obstruction and airway inflammation in asthma: a review. Lung 2006; 184: 251–258.
59.
Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR; American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications: An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184: 602–615.
60.
Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, Hunt JF, Kita H, Liu AH, Panettieri RA Jr, Schleimer RP, Minnicozzi M: Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012; 129 (3 suppl):S9–S23.
61.
Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373. Erratum in: Eur Respir J 2014; 43: 1216.
62.
Wechsler ME: Getting control of uncontrolled asthma. Am J Med 2014; 127: 1049–1059.
63.
Wilson SR, Strub P, Buist AS, Knowles SB, Lavori PW, Lapidus J, Vollmer WM; Better Outcomes of Asthma Treatment (BOAT) Study Group: Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med 2010; 181: 566–577.
64.
Haahtela T, Tuomisto LE, Pietinalho A, Klaukka T, Erhola M, Kaila M, Nieminen MM, Kontula E, Laitinen LA: A 10 year asthma programme in Finland: major change for the better. Thorax 2006; 61: 663–670.
65.
Roth M, Johnson PR, Rüdiger JJ, King GG, Ge Q, Burgess JK, Anderson G, Tamm M, Black JL: Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360: 1293–1299.
66.
Busse WW, Pedersen S, Pauwels RA, Tan WC, Chen YZ, Lamm CJ, O’Byrne PM; START Investigators Group: The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2008; 121: 1167–1174.
67.
O’Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW; START Investigators Group: Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009; 179: 19–24. Erratum in: Am J Respir Crit Care Med 2010; 182: 983–984.
68.
Welsh EJ, Cates CJ: Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma. Cochrane Database Syst Rev 2010; 9:CD008418.
69.
O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A: Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392–1397.
70.
Adams NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW: Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2005; 1:CD002738.
71.
Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B: Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332–336.
72.
Chauhan BF, Ducharme FM: Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2012; 5:CD002314.
73.
Schafroth Török S, Mueller T, Miedinger D, Jochmann A, Zellweger LJ, Sauter S, Goll A, Chhajed PN, Taegtmeyer AB, Knöpfli B, Leuppi JD: An open-label study examining the effect of pharmacological treatment on mannitol- and exercise-induced airway hyperresponsiveness in asthmatic children and adolescents with exercise-induced bronchoconstriction. BMC Pediatr 2014; 14: 196.
74.
Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ: A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy 2001; 31: 616–624.
75.
Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ: Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010; 5:CD005535.
76.
Ni Chroinin M, Lasserson TJ, Greenstone I, Ducharme FM: Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2009; 3:CD007949.
77.
Bateman ED, Harrison TW, Quirce S, Reddel HK, Buhl R, Humbert M, Jenkins CR, Peterson S, Ostlund O, O’Byrne PM, Sears MR, Eriksson GS: Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res 2011; 12: 38.
78.
Powell H, Gibson PG: Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust 2003; 178: 223–225.
79.
Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O’Byrne P, Barnes PJ, Ullman A: Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405–1411. Erratum in: N Engl J Med 1998; 338: 139.
80.
Rodrigo GJ, Castro-Rodríguez JA: What is the role of tiotropium in asthma? A systematic review with meta-analysis. Chest 2015; 147: 388–396.
81.
Rodrigo GJ, Neffen H, Castro-Rodriguez JA: Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139: 28–35.
82.
Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID: Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973–984.
83.
Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P: Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double- blind, placebo-controlled trial. Lancet 2012; 380: 651–659.
84.
Sont JK: How do we monitor asthma control? Allergy 1999; 54(suppl 49): 68–73.
85.
FitzGerald JM, Boulet LP, Follows RM: The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an ad justable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther 2005; 27: 393–406.
86.
Rank MA, Hagan JB, Park MA, Podjasek JC, Samant SA, Volcheck GW, Erwin PJ, West CP: The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013; 131: 724–729.
87.
Abramson MJ, Puy RM, Weiner JM: Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010; 8:CD001186.
88.
Normansell R, Kew KM, Bridgman A: Sublingual immunotherapy for asthma. Cochrane Database Syst Rev 2015; 8:CD011293.
89.
Gøtzsche PC, Johansen HK: House dust mite control measures for asthma. Cochrane Database Syst Rev 2008; 2:CD001187.
90.
Platts-Mills TA: Allergen avoidance in the treatment of asthma: problems with the meta-analyses. J Allergy Clin Immunol. 2008; 122: 694–696.
91.
Cates CJ, Rowe BH: Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev 2013; 2:CD000364.
92.
Talbot TR, Hartert TV, Mitchel E, Halasa NB, Arbogast PG, Poehling KA, Schaffner W, Craig AS, Griffin MR: Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med 2005; 352: 2082–2090.
93.
Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL, Fiss E, Olivenstein R, Thomson NC, Niven RM, Pavord ID, Simoff M, Duhamel DR, McEvoy C, Barbers R, Ten Hacken NH, Wechsler ME, Holmes M, Phillips MJ, Erzurum S, Lunn W, Israel E, Jarjour N, Kraft M, Shargill NS, Quiring J, Berry SM, Cox G; AIR2 Trial Study Group: Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010; 181: 116–124.
94.
Wechsler ME, Laviolette M, Rubin AS, Fiterman J, Lapa e Silva JR, Shah PL, Fiss E, Olivenstein R, Thomson NC, Niven RM, Pavord ID, Simoff M, Hales JB, McEvoy C, Slebos DJ, Holmes M, Phillips MJ, Erzurum SC, Hanania NA, Sumino K, Kraft M, Cox G, Sterman DH, Hogarth K, Kline JN, Mansur AH, Louie BE, Leeds WM, Barbers RG, Austin JH, Shargill NS, Quiring J, Armstrong B, Castro M; Asthma Intervention Research 2 Trial Study Group: Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol 2013; 132: 1295–1302.
95.
Chupp G, Laviolette M, Cohn L, McEvoy C, Bansal S, Shifren A, Khatri S, Grubb GM, McMullen E, Strauven R, Kline JN; other members of the PAS2 Study Group: Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre studies. Eur Respir J 2017; 50: 1700017. Erratum in: Eur Respir J 2017; 50(4).
96.
Steurer-Stey C, Storch M, Benz S, Hobi B, Steffen-Bürgi B, Steurer J, Puhan MA: Motivational training improves self-efficacy but not short-term adherence with asthma self-management: a randomized controlled trial. Prim Health Care Res Dev 2015; 16: 32–41.
97.
Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, Serra M, Scichilone N, Sestini P, Aliani M, Neri M; Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri: Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011; 105: 930–938. Erratum in: Respir Med 2012; 106: 757.
98.
Boulet LP, Vervloet D, Magar Y, Foster JM: Adherence: the goal to control asthma. Clin Chest Med 2012; 33: 405–417.
99.
Price D, Robertson A, Bullen K, Rand C, Horne R, Staudinger H: Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med 2010; 10: 1.
100.
Powell H, Gibson PG: Options for self-management education for adults with asthma. Cochrane Database Syst Rev 2003; 1:CD004107.
101.
Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood P, Bauman A, Hensley MJ, Walters EH: Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 2003; 1:CD001117.
102.
McLean S, Chandler D, Nurmatov U, Liu J, Pagliari C, Car J, Sheikh A: Telehealthcare for asthma. Cochrane Database Syst Rev 2010; 10:CD007717.
103.
Boulet LP: Influence of comorbid conditions on asthma. Eur Respir J 2009; 33: 897–906.
104.
Lavoie KL, Bacon SL, Labrecque M, Cartier A, Ditto B: Higher BMI is associated with worse asthma control and quality of life but not asthma severity. Respir Med 2006; 100: 648–657.
105.
Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DY: Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med 2008; 178: 682–687.
106.
Moreira A, Bonini M, Garcia-Larsen V, Bonini S, Del Giacco SR, Agache I, Fonseca J, Papadopoulos NG, Carlsen KH, Delgado L, Haahtela T: Weight loss interventions in asthma: EAACI evidence-based clinical practice guideline (part I). Allergy 2013; 68: 425–439.
107.
Adeniyi FB, Young T: Weight loss interventions for chronic asthma. Cochrane Database Syst Rev 2012; 7:CD009339.
108.
Kiljander TO, Harding SM, Field SK, Stein MR, Nelson HS, Ekelund J, Illueca M, Beckman O, Sostek MB: Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2006; 173: 1091–1097.
109.
Lavoie KL, Cartier A, Labrecque M, Bacon SL, Lemière C, Malo JL, Lacoste G, Barone S, Verrier P, Ditto B: Are psychiatric disorders associated with worse asthma control and quality of life in asthma patients? Respir Med 2005; 99: 1249–1257.
110.
Ahmedani BK, Peterson EL, Wells KE, Williams LK: Examining the relationship between depression and asthma exacerbations in a prospective follow-up study. Psychosom Med 2013; 75: 305–310.
111.
Yorke J, Fleming SL, Shuldham CM: Psychological interventions for adults with asthma. Cochrane Database Syst Rev 2006; 1:CD002982.
112.
Bock SA, Muñoz-Furlong A, Sampson HA: Further fatalities caused by anaphylactic reactions to food, 2001–2006. J Allergy Clin Immunol 2007; 119: 1016–1018.
113.
Cruz AA, Popov T, Pawankar R, Annesi-Maesano I, Fokkens W, Kemp J, Ohta K, Price D, Bousquet J; ARIA Initiative Scientific Committee: Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy 2007; 62(suppl 84): 1–41.
114.
Hamilos DL: Chronic rhinosinusitis: epidemiology and medical management. J Allergy Clin Immunol 2011; 128: 693–707.
115.
Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schünemann HJ; Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group: Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126: 466–476.
116.
Szczeklik A, Nizankowska E, Duplaga M: Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000; 16: 432–436.
117.
Leuppi JD: Bronchoprovocation tests in asthma: direct versus indirect challenges. Curr Opin Pulm Med 2014; 20: 31–36.
118.
Nizankowska E, Bestyńska-Krypel A, Cmiel A, Szczeklik A: Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000; 15: 863–869.
119.
El Miedany Y, Youssef S, Ahmed I, El Gaafary M: Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2006; 97: 105–109.
120.
Szczeklik A, Stevenson DD: Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 1999; 104: 5–13.
121.
Gluck JC, Gluck PA: The effect of pregnancy on the course of asthma. Immunol Allergy Clin North Am 2006; 26: 63–80.
122.
Murphy VE, Clifton VL, Gibson PG: Asthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes. Thorax 2006; 61: 169–176.
123.
Murphy VE, Gibson PG: Asthma in pregnancy. Clin Chest Med 2011; 32: 93–110.
124.
Schatz M, Leibman C: Inhaled corticosteroid use and outcomes in pregnancy. Ann Allergy Asthma Immunol 2005; 95: 234–238.
125.
Lim A, Stewart K, König K, George J: Systematic review of the safety of regular preventive asthma medications during pregnancy. Ann Pharmacother 2011; 45: 931–945.
126.
Gibson PG, McDonald VM, Marks GB: Asthma in older adults. Lancet 2010; 376: 803–813.
127.
Reed CE: Asthma in the elderly: diagnosis and management. J Allergy Clin Immunol 2010; 126: 681–687.
128.
Smetana GW, Lawrence VA, Cornell JE; American College of Physicians: Preoperative pulmonary risk stratification for noncardiothoracic surgery: systematic review for the American College of Physicians. Ann Intern Med 2006; 144: 581–595.
129.
Woods BD, Sladen RN: Perioperative considerations for the patient with asthma and bronchospasm. Br J Anaesth 2009; 103(suppl 1):i57–i65.
130.
Hashimoto S, Bel EH: Current treatment of severe asthma. Clin Exp Allergy 2012; 42: 693–705.
131.
Chipps BE, Zeiger RS, Borish L, Wenzel SE, Yegin A, Hayden ML, Miller DP, Bleecker ER, Simons FE, Szefler SJ, Weiss ST, Haselkorn T; TENOR Study Group: Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol 2012; 130: 332–342.
132.
Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O’Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Sullivan SD, Szefler SJ, Thomas MD, Wenzel SE; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations: An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59–99.
133.
Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A: Differences between asthma exacerbations and poor asthma control. Lancet 1999; 353: 364–369. Erratum in Lancet 1999; 353: 758.
134.
Leuppi JD, Salome CM, Jenkins CR, Anderson SD, Xuan W, Marks GB, Koskela H, Brannan JD, Freed R, Andersson M, Chan HK, Woolcock AJ: Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163: 406–412.
135.
Ramnath VR, Clark S, Camargo CA: Multicenter study of clinical features of sudden-onset versus slower-onset asthma exacerbations requiring hospitalization. Respir Care 2007; 52: 1013–1020.
136.
Alvarez GG, Schulzer M, Jung D, Fitzgerald JM: A systematic review of risk factors associated with near-fatal and fatal asthma. Can Respir J 2005; 12: 265–270.
137.
Suissa S, Blais L, Ernst P: Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J 1994; 7: 1602–1609.
138.
Reddeck HK, Barnes DJ: Pharmacological strategies for self-management of asthma exacerbations. Eur Respir J 2006; 28: 182–199.
139.
Cates CJ, Karner C: Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev 2013; 4:CD007313.
140.
Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, Fabbri LM, Rabe KF: Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med 2013; 1: 23–31.
141.
Patel M, Pilcher J, Pritchard A, Perrin K, Travers J, Shaw D, Holt S, Harwood M, Black P, Weatherall M, Beasley R; SMART Study Group: Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med 2013; 1: 32–42.
142.
Cates CJ, Welsh EJ, Rowe BH: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2013; 9:CD000052.
143.
Newman KB, Milne S, Hamilton C, Hall K: A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma. Chest 2002; 121: 1036–1041.
144.
Travers AH, Milan SJ, Jones AP, Camargo CA Jr, Rowe BH: Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma. Cochrane Database Syst Rev 2012; 12:CD010179.
145.
Manser R, Reid D, Abramson M: Corticosteroids for acute severe asthma in hospitalised patients. Cochrane Database Syst Rev 2001; 1:CD001740.
146.
Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW: Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev 2007; 3:CD000195.
147.
Hasegawa T, Ishihara K, Takakura S, Fujii H, Nishimura T, Okazaki M, Katakami N, Umeda B: Duration of systemic corticosteroids in the treatment of asthma exacerbation; a randomized study. Intern Med 2000; 39: 794–797.
148.
Jones AM, Munavvar M, Vail A, Aldridge RE, Hopkinson L, Rayner C, O’Driscoll BR: Prospective, placebo-controlled trial of 5 vs 10 days of oral prednisolone in acute adult asthma. Respir Med 2002; 96: 950–954.
149.
Edmonds ML, Milan SJ, Camargo CA Jr, Pollack CV, Rowe BH: Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev 2012; 12:CD002308.
150.
Rodrigo GJ, Castro-Rodriguez JA: Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax 2005; 60: 740–746.
151.
Rowe BH, Bretzlaff JA, Bourdon C, Bota GW, Camargo CA Jr: Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database Syst Rev 2000; 2:CD001490.
152.
Gallegos-Solórzano MC, Pérez-Padilla R, Hernández-Zenteno RJ: Usefulness of inhaled magnesium sulfate in the coadjuvant management of severe asthma crisis in an emergency department. Pulm Pharmacol Ther 2010; 23: 432–437.
153.
Schatz M, Rachelefsky G, Krishnan JA: Follow-up after acute asthma episodes: what improves future outcomes? Proc Am Thorac Soc 2009; 6: 386–393.
154.
Gibson PG, Simpson JL: The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64: 728–735.
155.
Mannino DM, Gagnon RC, Petty TL, Lydick E: Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 2000; 160: 1683–1689.
156.
Sin DD, Miravitlles M, Mannino DM, Soriano JB, Price D, Celli BR, Leung JM, Nakano Y, Park HY, Wark PA, Wechsler ME: What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J 2016; 48: 664–673.
157.
Kauppi P, Kupiainen H, Lindqvist A, Tammilehto L, Kilpeläinen M, Kinnula VL, Haahtela T, Laitinen T: Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma 2011; 48: 279–285.
158.
Weatherall M, Travers J, Shirtcliffe PM, Marsh SE, Williams MV, Nowitz MR, Aldington S, Beasley R: Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 2009; 34: 812–818.
159.
van Schayck CP, Levy ML, Chen JC, Isonaka S, Halbert RJ: Coordinated diagnostic approach for adult obstructive lung disease in primary care. Prim Care Respir J 2004; 13: 218–221.
160.
Price DB, Tinkelman DG, Halbert RJ, Nordyke RJ, Isonaka S, Nonikov D, Juniper EF, Freeman D, Hausen T, Levy ML, Ostrem A, van der Molen T, van Schayck CP: Symptom-based questionnaire for identifying COPD in smokers. Respiration 2006; 73: 285–295.
161.
Halbert RJ, Isonaka S: International Primary Care Respiratory Group (IPCRG) Guidelines: integrating diagnostic guidelines for managing chronic respiratory diseases in primary care. Prim Care Respir J 2006; 15: 13–19.
162.
Global Initiative for Chronic Obstructive Lung Diseases (GOLD). Global strategy for diagnosis, management and prevention of COPD. 2014. www.goldcopd.org.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.